CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Price Target of $9.71 According to Brokerages

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have received an average rating of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.86.

A number of equities analysts have recently issued reports on CAMP shares. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Oppenheimer initiated coverage on CAMP4 Therapeutics in a research note on Monday. They set an “outperform” rating and a $15.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Finally, Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th.

Insider Buying and Selling

In other CAMP4 Therapeutics news, Director Andrew Schwab sold 400,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $4.04, for a total value of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. The trade was a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Young acquired 16,378 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. The trade was a 9.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. 21.69% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAMP. Jefferies Financial Group Inc. acquired a new position in CAMP4 Therapeutics in the fourth quarter worth $70,000. Bank of America Corp DE acquired a new stake in shares of CAMP4 Therapeutics in the second quarter valued at $78,000. Deutsche Bank AG bought a new position in shares of CAMP4 Therapeutics in the second quarter valued at about $138,000. Bank of New York Mellon Corp bought a new position in shares of CAMP4 Therapeutics in the second quarter valued at about $365,000. Finally, EcoR1 Capital LLC bought a new stake in CAMP4 Therapeutics during the 4th quarter worth about $1,992,000.

CAMP4 Therapeutics Stock Down 1.2%

NASDAQ CAMP opened at $3.96 on Wednesday. CAMP4 Therapeutics has a twelve month low of $2.86 and a twelve month high of $7.75. The stock has a market cap of $248.49 million, a P/E ratio of -1.71 and a beta of 0.27. The company’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $4.23.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The business had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Research analysts anticipate that CAMP4 Therapeutics will post -0.57 earnings per share for the current year.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.